Moderna (MRNA) announced that the Australian Therapeutic Goods Administration has granted approval for mRESVIA, an mRNA respiratory syncytial virus vaccine, to prevent lower respiratory tract disease caused by RSV infection in adults aged 60 years and older.1 mRESVIA’s approval marks a significant milestone as it is the first mRNA vaccine in Australia approved for use against a disease beyond COVID-19. The approval is based on positive data from the Phase 3 clinical trial ConquerRSV, a randomized, placebo-controlled, observer-blind, case-driven clinical study conducted in approximately 37,000 adults aged 60 years or older in 22 countries.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- U.S. to end funding for child vaccines in developing countries, NY Times reports
- Moderna price target lowered to $33 from $40 at JPMorgan
- Craig-Hallum bullish on Personalis, initiates with a Buy
- Early notable gainers among liquid option names on March 13th
- Microsoft, Intel upgraded: Wall Street’s top analyst calls